

#### 26 **Supplementary Note 1: Probability of detection**

27 Here, we derive the expression given in the main text for the probability,  $p_d(\tau)$ , 28 of an infected individual, subject to regular antigen testing, having been detected by 29 time since infection  $\tau$ . We assume (as in most of our analyses) an exponentially 30 distributed interval of mean  $T$  between successive tests (i.e., a constant rate of 31 testing).

32 First, since we assume that symptomatic hosts are always detected, we have 33  $p_d(\tau) = 1$  for  $\tau \ge \tau_{inc}$ , where  $\tau_{inc}$  is the individual's incubation period (which can be 34 taken to be infinite to represent an entirely asymptomatic infection). Now, for  $\tau < \tau_{\text{inc}}$ , 35 we consider a short time interval  $[\tau, \tau + d\tau]$ . The probability that the individual returns 36 a positive antigen test in this interval is given (up to terms of order  $d\tau^2$ ) by 37  $(1/T) d\tau \times p_{+}(V(\tau))$ , where  $(1/T) d\tau$  represents the probability of taking a test, and 38  $p_{+}(V(\tau))$  the probability that the result of a test is positive (which depends on the 39 instantaneous viral load,  $V(\tau)$ ). Conditioning on whether or not a positive test is 40 returned in the interval  $[\tau, \tau + d\tau]$  then gives

44 
$$
p_d(\tau + d\tau) = 1 \times \frac{p_+(V(\tau))d\tau}{T} + p_d(\tau) \times \left(1 - \frac{p_+(V(\tau))d\tau}{T}\right),
$$

41 where the probability of detection by time  $(\tau + d\tau)$  conditional on a positive test in  $\{\tau, \tau + d\tau\}$  is 1, and the probability conditional on no positive test in that interval is 43  $p_d(\tau)$ .

45 Rearranging the above equation and taking the limit  $d\tau \rightarrow 0$  gives the 46 differential equation,

48 
$$
\frac{dp_d}{d\tau} = \frac{p_+(V(\tau))}{T} (1 - p_d(\tau)),
$$

47 which can be solved alongside the initial condition  $p_d(0) = 0$  to obtain

50 
$$
p_d(\tau) = 1 - \exp\left(-\frac{1}{T}\int_0^{\tau} p_+(V(x))dx\right),
$$

49 for  $\tau < \tau_{\text{inc}}$ .

#### 52 **Supplementary Note 2: Derivation of outbreak risk**

 Below, we derive an analytical expression for the outbreak risk in a 54 heterogeneous population divided into  $n$  subgroups (the special case of a 55 homogeneous population is obtained when  $n = 1$ ), between which the infectiousness profile of infected hosts (as well as other factors such as susceptibility) may vary. Specifically, we consider a branching process model in which susceptible depletion is neglected and infection lineages are assumed to be independent. The outbreak risk is then taken to be the probability that epidemic extinction does *not* occur within this branching process framework, following the introduction of a single newly infected host into the population, i.e., the probability that the number of currently infected individuals never reaches zero but instead tends to infinity (note that in reality, the assumptions underlying the branching process model will no longer be valid when the number of infected individuals becomes large).

65 We suppose that each infected host in group  *transmits the pathogen to* 66 individuals in group *i* at total rate  $\beta_{i,j}(\tau)$  at time since infection  $\tau$  (a specific form of 67  $\beta_{i,j}(\tau)$  is considered later). The expected total number of infections generated in group 68  $i$  by each infected host in group  $j$  (over the course of infection) is then

$$
R_{i,j} = \int_0^\infty \beta_{i,j}(\tau) d\tau,
$$

69 where the basic reproduction number (accounting for regular antigen testing if in 70 place),  $R_{0,eff}$ , is the largest eigenvalue of the matrix with entries  $R_{i,j}$  (the next-71 generation matrix) (1).

73 Now, we suppose that a single infected individual in group  *is introduced into* 74 the population at time since infection  $\tau$ , with the remainder of the population assumed 75 to be uninfected at the time of introduction (and assuming no further external pathogen 76 introductions into the population). Then an expression for the probability of extinction 77 (i.e., the probability that a major outbreak does *not* occur), denoted  $q_i(\tau)$ , can be 78 derived by conditioning on whether or not the initial infected individual transmits the 79 pathogen (to an individual in any population group) between times since infection  $\tau$ 80 and  $(\tau + d\tau)$ , to obtain (neglecting the possibility that multiple transmissions occur, 81 which has probability of order  $d\tau^2$ )

82 
$$
q_j(\tau) = \left(\sum_{i=1}^n q_j(\tau + d\tau)q_i(0) \times \beta_{i,j}(\tau) d\tau\right) + q_j(\tau + d\tau) \times \left(1 - \sum_{i=1}^n \beta_{i,j}(\tau) d\tau\right).
$$

83 Here,  $\beta_{i,j}(\tau) d\tau$  gives the probability of a transmission to an individual in group i 84 occurring in this time interval,  $q_j(\tau + d\tau)q_i(0)$  the extinction probability conditional on 85 such a transmission occurring (since infection lineages are assumed to be 86 independent), and  $q_i(\tau + d\tau)$  the extinction probability conditional on no 87 transmissions occurring.

88 Rearranging the above equation and taking the limit  $d\tau \to 0$  gives the 89 differential equation,

91 
$$
\frac{dq_j}{d\tau} = q_j(\tau) \sum_{i=1}^n (1 - q_i(0)) \beta_{i,j}(\tau),
$$

90 which can be solved alongside the boundary condition  $q_i(\infty) = 1$  to obtain

93 
$$
q_j(\tau) = \exp\left(-\sum_{i=1}^n (1 - q_i(0)) \int_\tau^\infty \beta_{i,j}(x) dx\right).
$$

92 In particular, we have

94 
$$
q_j(0) = \exp\bigg(-\sum_{i=1}^n (1 - q_i(0))R_{i,j}\bigg).
$$

95 Now, a relatively general parameterisation is to take  $\beta_{i,j}(\tau) = \varepsilon_i \eta_i C_{i,j} \beta_j(\tau)$ , so 96 that  $R_{i,j} = \varepsilon_i \eta_i C_{i,j} B_j$ . Here,  $\beta_j(\tau)$  is the infectiousness profile of an infected individual 97 in group j,  $B_j$  is the total integral of  $\beta_j(\tau)$  over all times since infection,  $\varepsilon_i$  is the 98 proportion of the population who are in group i,  $\eta_i$  is the relative susceptibility in group 99 *i*, and  $C_{i,j}$  represents the rate of contacts between individuals in groups *i* and *j*. The 100 above equation can be used to calculate the outbreak risk for general  $\beta_{i,j}(\tau)$ . 101 However, further analytic progress is possible under the assumption of homogeneous 102 mixing (i.e., when  $C_{i,j}$  is independent of i and j). Absorbing the value of  $C_{i,j}$  into 103  $\beta_{i,j}(\tau)$  (i.e., setting  $C_{i,j} = 1$ ), we then have

104 
$$
q_j(0) = \exp\left(-B_j \sum_{i=1}^n (1 - q_i(0)) \varepsilon_i \eta_i\right).
$$
 (S1)

105 In this case, the overall extinction probability following the introduction of a 106 single newly infected individual is

107 
$$
q(0) = \frac{1}{\bar{\eta}} \sum_{j=1}^{n} \varepsilon_j \eta_j q_j(0) = \sum_{j=1}^{n} a_j q_j(0),
$$
 (S2)

108 where  $\bar{\eta} = \sum_{j=1}^n \varepsilon_j \eta_j$  gives the mean population susceptibility, and  $a_j = \varepsilon_j \eta_j / \bar{\eta}$  gives 109 the proportion of new infections that are in group  $j$ . Now, Eq. (S1) above can be written 110 as

112 
$$
q_j(0) = \exp(-(1 - q(0))\bar{\eta}B_j),
$$

111 and substituting this expression into Eq. (S2) then gives

115 
$$
q(0) = \frac{1}{\overline{\eta}} \sum_{j=1}^{n} \varepsilon_j \eta_j \exp(-(1 - q(0))\overline{\eta}B_j) = \sum_{j=1}^{n} a_j \exp(-(1 - q(0))R_j),
$$
 (S3)

113 where  $R_i = \bar{\eta}B_i$  gives the expected number of transmissions generated by an infected 114 host in group  $j$  (over the course of infection).

116 Finally, the outbreak risk (following the introduction of a single newly infected 117 individual into an otherwise susceptible population),  $p_{\text{outbreak}} = 1 - q(0)$ , then 118 satisfies

126 
$$
p_{\text{outbreak}} = 1 - \sum_{j=1}^{n} a_j \times \exp(-R_j \times p_{\text{outbreak}}),
$$

 which is Eq. (2) in the main text. While this equation may have multiple solutions (in 120 particular,  $p_{\text{outbreak}} = 0$  is always a solution), by standard theory of hitting probabilities on Markov chains (2), the relevant solution is the largest solution between 122 0 and 1 (since the relevant solution to Eq. (S3) is the minimal non-negative one). While we focussed on the outbreak risk starting with a single, newly infected, primary case, it would be straightforward to consider an infected individual introduced into the population later in infection, and/or multiple pathogen introductions, in our approach.

127 We note that the basic reproduction number in this scenario (accounting for 128 regular antigen testing, if carried out) is

132 
$$
R_{0,\text{eff}} = \sum_{i=1}^{n} \varepsilon_i \eta_i B_i = \sum_{i=1}^{n} a_i R_i,
$$

129 where the first equality follows since the next-generation matrix is of separable form 130  $R_{i,j} = c_i d_j$  (where here  $c_i = \varepsilon_i \eta_i$  and  $d_j = B_j$ ) and therefore has largest eigenvalue 131  $R_{0,\text{eff}} = \sum_{i=1}^{n} c_i d_i$  (1). This can also be written as

135 
$$
R_{0,\text{eff}} = \int_0^\infty \bar{\beta}(\tau) d\tau,
$$

133 where  $\bar{\beta}(\tau) = \bar{\eta} \sum_{i=1}^n a_i \beta_i(\tau)$  gives the expected infectiousness profile, accounting for 134 the relative susceptibility of the population. We also note that while the derivation

- here includes the possibility of heterogeneous susceptibility between different
- population sub-groups, we did not consider heterogeneous susceptibility in our

numerical analyses.

- 139 In the special case of a homogeneous population  $(n = 1)$ , we have
- 142  $p_{\text{outbreak}} = 1 \exp(-R_{0,\text{eff}} \times p_{\text{outbreak}})$ ,
- i.e. we recover Eq. (1) in the main text.

#### **Supplementary Note 3: Wider applicability of outbreak risk equation accounting**

#### **for heterogeneity**

 The result in Eq. (2), while derived in the context of a time-since-infection model in a heterogeneous population, is in fact widely applicable to a range of (branching process) models. Specifically, taking the limit of a continuous distribution of population subgroups in Eq. (2) gives the equation

157 
$$
p_{\text{outbreak}} = 1 - \int_{\Theta} a(\theta) \times \exp(-R(\theta) \times p_{\text{outbreak}}) d\theta. \tag{S4}
$$

149 Here  $\theta \in \Theta$  is a continuous variable (which may be either real-valued or higher-150 dimensional) indexing population sub-groups and/or possible "types" of infection,  $a(\theta)$ 151 is the probability density that a new infection is of type  $\theta$ , and  $R(\theta)$  gives the expected 152 total number of transmissions generated by an infected host with infection type  $\theta$ . We briefly note that the continuous formulation in Eq. (S4) is applicable to the scenario of heterogeneous within-host dynamics that we considered, but in practice it was easier to calculate the outbreak risk by sampling the within-host dynamics of a large number of hosts and using Eq. (2).

 As an example to demonstrate the applicability of Eq. (S4), we consider a branching process approximation of the stochastic SIR compartmental epidemic model. In this case, the possible "types" of infection are indexed by the infectious 161 period,  $\theta = t_1 \in [0, \infty)$ , with  $a(\theta) = \mu \exp(-\mu t_1)$  (i.e., an exponentially distributed 162 infectious period is assumed) and  $R(\theta) = R_0 \mu t_i$  (i.e., the expected number of transmissions by an infected host is proportional to their infectious period). Substituting into Eq. (S4) then gives

167 
$$
p_{\text{outbreak}} = 1 - \int_0^\infty \mu \exp(-(1 + R_0 p_{\text{outbreak}}) \mu t_I) dt_I.
$$

 Integrating and taking the largest solution between 0 and 1 of the resulting quadratic equation then reproduces the well-known formula,

$$
p_{\text{outbreak}} = \max\Big\{1 - \frac{1}{R_0}, 0\Big\}.
$$

 Similarly, the outbreak risk under branching process approximations of a wide range of more complex compartmental models, for example models with non-exponentially distributed infectious periods and/or age structure, can also be represented using Eq. (S4).

#### 173 **Supplementary Note 4: Outbreak risk under delayed and/or time-limited regular**

## 174 **antigen testing**

 Here, we generalise our results to obtain an expression for the outbreak risk in scenarios where regular antigen testing is introduced reactively after an infection occurs and/or is only in place for a limited period of time. For simplicity, we consider homogeneous within-host dynamics (although the derivation presented here readily generalises to a heterogeneous population), supposing that each host infected at 180 calendar time t transmits the pathogen at rate  $\beta(\tau,t)$  at time since infection  $\tau$  (i.e., 181 at calendar time  $(t + \tau)$ ). Below, we first derive the outbreak risk for general  $\beta(\tau,t)$ , 182 before deriving a specific form of  $\beta(\tau,t)$  under delayed and/or time-limited regular antigen testing.

184 We suppose that an infected individual, who was infected at calendar time  $t$ , is 185 introduced into an otherwise uninfected population at time since infection  $\tau$  (at 186 calendar time  $(t + \tau)$ ). Then, conditioning on whether or not the initial infected host 187 transmits the pathogen between times since infection  $\tau$  and  $(\tau + d\tau)$  (and assuming 188 no more external infections), we find that the extinction probability,  $q(\tau,t)$ , satisfies 189 (up to terms of order  $d\tau^2$ )

191 
$$
q(\tau,t) = q(\tau + d\tau,t)q(0,t+\tau+d\tau) \times \beta(\tau,t)d\tau + q(\tau+d\tau,t) \times (1-\beta(\tau,t)d\tau).
$$

190 Rearranging and taking the limit  $d\tau \rightarrow 0$  gives the differential equation,

193 
$$
\frac{\partial q}{\partial \tau} = q(\tau, t) \big( 1 - q(0, t + \tau) \big) \beta(\tau, t),
$$

192 which can be solved alongside the boundary condition  $q(\infty,t) = 1$  to obtain

195 
$$
q(\tau,t) = \exp\left(-\int_{\tau}^{\infty} (1 - q(0, t + \tilde{\tau})) \beta(\tilde{\tau}, t) d\tilde{\tau}\right).
$$

194 In particular, we have

199 
$$
q(0,t) = \exp\left(-\int_0^\infty (1-q(0,t+\tau))\beta(\tau,t)d\tau\right),
$$

196 (where we have relabelled  $\tilde{\tau}$  from the previous equation as  $\tau$ ) and the outbreak risk, 197  $p_{\text{outbreak}}(t) = 1 - q(0,t)$ , following the introduction of a single newly infected host at 198 time  $t$ , is therefore the largest solution between 0 and 1 of the equation

200 
$$
p_{\text{outbreak}}(t) = 1 - \exp\left(-\int_0^\infty p_{\text{outbreak}}(t+\tau)\beta(\tau,t)d\tau\right).
$$
 (S5)

201 We now derive the form of  $\beta(\tau,t)$  under delayed and/or time-limited regular 202 antigen testing. Specifically, we suppose that testing only takes place between 203 calendar times  $t_{\text{start}}$  and  $t_{\text{end}}$ , and that within that time period, the interval between 204 tests (for a specified individual) is exponentially distributed with mean  $T$ . A similar 205 argument to that in **Supplementary Note 1** can be used to show that the probability, 206  $p_d(\tau,t)$ , of an individual infected at calendar time t having been detected by time 207 since infection  $\tau < \tau_{\text{inc}}$  (where  $\tau_{\text{inc}}$  is the incubation period, with  $p_d(\tau, t) = 1$  for  $\tau \ge$ 208  $\tau_{\text{inc}}$ ), is

$$
214
$$

214 
$$
p_d(\tau,t) = 1 - \exp\left(-\frac{1}{T}\int_{\max\{0,\min\{\tau,\,t_{\text{start}}-t\}\}}^{\max\{0,\min\{\tau,\,t_{\text{start}}-t\}\}} p_+(V(x))dx\right),
$$

209 where  $p_{+}(V(x))$  gives the probability that the result of a test taken at time since 210 infection  $x$  is positive, and the limits of the integral give the times since infection up to 211  $\tau$  over which the regular antigen testing policy is in place. The (calendar time-212 dependent) expected infectiousness profile, accounting for different possible detection 213 times, is then

217 
$$
\beta(\tau,t) = \left[\alpha_d p_d(\tau,t) + \left(1 - p_d(\tau,t)\right)\right] \times \beta_u(\tau),
$$

215 where  $\beta_u(\tau)$  is the infectiousness profile of an undetected individual at time since 216 infection  $\tau$ , and  $\alpha_d$  is the relative infectiousness of a detected host.

218 Finally, we consider a scenario in which regular antigen testing is introduced 219 after a delay of  $x_{\text{del}}$  from the time of the first infection (where we may expect  $x_{\text{del}}$  to 220 be at least the length of the incubation period), and is carried out over a finite duration 221 of time,  $x_{dur}$ . This scenario can be represented by taking  $t_{start} = 0$  and  $t_{end} = x_{dur}$ 222 in the above, and then using Eq. (S5) to calculate  $p_{\text{outbreak}}(-x_{\text{del}})$  numerically. In this 223 scenario, for  $t \geq t_{end}$ ,  $p_{\text{outbreak}}(t)$  is simply the outbreak risk in the absence of 224 antigen testing (which is independent of  $t$  and can be calculated using Eq. (1) in the 225 main text). Eq. (S5) can therefore be solved iteratively on a grid of  $t \in [-x_{\text{del}}, t_{\text{end}}]$  by 226 considering successively lower  $t$  values and each time discretising the integral in Eq. 227 (S5) to calculate  $p_{\text{outbreak}}(t)$ , since Eq. (S5) allows  $p_{\text{outbreak}}(t)$  to be calculated once 228  $p_{\text{outbreak}}(x)$  is known for  $x > t$ .

229 We note that the above numerical scheme in fact gives the outbreak risk for a 230 grid of delays from 0 up to and including  $x_{\text{del}}$  (for a fixed duration,  $x_{\text{dur}}$ ). If there is no 231 delay, then it is convenient to instead take  $t_{start} = -\infty$  and  $t_{end} = 0$ , and to calculate 232  $p_{\text{outbreak}}(t)$  on a grid of negative t in order to obtain the outbreak risk for different  durations of regular antigen testing (although we note that this scenario is unlikely to be of real-world relevance, unless an infection occurs shortly before the scheduled end of an ongoing regular antigen testing program).

#### 237 **Supplementary Note 5: Details of discrete-time stochastic outbreak simulation**

### 238 **algorithm**

 We verified our analytically derived estimates of the outbreak risk by comparing these estimates with corresponding estimates obtained through repeated simulation of a discrete-time, individual-based stochastic epidemic model (**Figure 2F** and **Supplementary Figure 2**). In this section, we describe the simulation model and how it was used to estimate the outbreak risk.

- 244 Prior to running each outbreak simulation, we first determined and discretised 245 the within-host dynamics that each individual,  $i$ , in the population would follow if ever 246 infected, according to the following steps:
- 247 1. Determine the individual's (continuous-time) viral load profile,  $V^{(i)}(\tau)$ , where  $\tau$  is 248 the time since infection, and their incubation period,  $\tau_{\text{inc}}^{(i)}$  (in **Figure 2F** and 249 **Supplementary Figure 2,** we assumed homogeneous within-host dynamics, but 250 in principle heterogeneity could be included).
- 251 2. Calculate the individual undetected infectiousness profile,  $\beta_u^{(i)}(\tau)$ , and probability 252 bot a test taken at time since infection  $\tau$  giving a positive result,  $p_{+}^{(i)}(\tau)$ , as 253 described in the main text (note that  $p_{+}^{(i)}$  is here defined as a function of time since 254 infection rather than viral load).
- 255 3. Sample the (potential) time,  $r^{(i)}$ , from the start of the day of infection to the exact 256 (potential) infection time, uniformly between zero and one day.
- 257 4. For each day since infection,  $\tau_{\text{discr}} \ge 1$  (where the day of infection is denoted day 258  $\qquad$  0), calculate the discretised infectiousness,  $\beta_{u,\text{discr}}^{(i)}(\tau_\text{discr})$ , as the average value 259 cof  $\beta_u^{(i)}(\tau)$  between times since infection  $(\tau_{discr} - \tau_i)$  and  $(\tau_{discr} - \tau_i + 1)$ . Note 260 that implicit in our simulation algorithm is the assumption that hosts cannot 261 transmit the pathogen on the day of infection (i.e.  $\beta_{u,discr}^{(i)}(0) = 0$ ).
- 262 5. Calculate the probability,  $p_{+,\text{discr}}^{(i)}(\tau_{\text{discr}}) = p_{+}^{(i)}(\tau_{\text{discr}} r_i)$ , of a test taken at the 263 start of day of infection  $\tau_{\text{discr}} \ge 1$  giving a positive result.
- 264 6. Calculate the discretised incubation period,  $\tau^{(i)}_{\text{inc,diser}} = \left| \left( r^{(i)} + \tau^{(i)}_{\text{inc}} \right) \right|$ . Note that we 265 only considered a single continuous incubation period, which exceeded 1, but if a 266 non-trivial distribution is used, then it should be truncated to take values of at least 267 1 in order to avoid symptom onset occurring on the day of infection.
- 268 7. Calculate the relative infectiousness on the day of symptom onset (assuming the 269 host is not detected before developing symptoms),  $\,\alpha_{o}^{(i)}$ , chosen to ensure that the 270 continuous- and discrete-time infectiousness profiles give the same expected 271 number of transmissions during this day (under the assumption of isolation 272 immediately following the exact symptom onset time).
- 273 8. Calculate the total duration of infection (up to loss of infectiousness),  $\tau_{\rm rec, discr}^{(i)}$ , as 274 the earliest day of infection for which  $\beta_u^{(i)}(\tau_{\rm discr}) = 0$  for all  $\tau_{\rm discr} \ge \tau_{\rm rec,discr}^{(i)}$ .
- 275 An example discretised infectiousness profile (without regular antigen testing) is 276 shown in **Supplementary Figure 2A**.

277 In the simulation algorithm, individuals are classified as being in one of the 278 following states on each day: susceptible  $(S)$ , infected but undetected  $(U)$ , infected 279 with symptom onset on the current day (and not detected prior to onset;  $\theta$ ), infected 280 and detected  $(D)$ , or recovered (specifically, no longer infectious following an infection; 281  $\,$  R). The O stage is included to allow for symptom onset (and therefore detection) 282 occurring at any time of day, whereas for simplicity we assumed that regular antigen 283 testing takes place only at the start of each day. The status of individual  $i$  (at a given 284 step in the simulation) is denoted by  $Y^{(i)} \in \{S, U, O, D, R\}$ . We write, for example, 285  $\mathbf{1}_S(Y^{(i)})$ , to denote the indicator function that takes the value 1 if  $Y^{(i)} = S$ , and 0 286 otherwise. However, we emphasise that the simulation model is not a compartmental 287 model, since different individuals of the same status are not treated identically.

288 Now, the simulation algorithm has the following inputs:

- 289 The population size,  $N$ .
- 290 The relative infectiousness of detected hosts,  $\alpha_d$ .
- 291 The relative susceptibility,  $\eta^{(i)}$ , of each individual, i (note that we assumed 292 homogeneous susceptibility in our analyses, i.e.,  $\eta^{(i)} = 1$  for each i).
- 293 The quantities  $\beta_{u,discr}^{(i)}(\tau_{discr})$ ,  $p_{+,discr}^{(i)}(\tau_{discr})$ ,  $\tau_{inc,discr}^{(i)}$ ,  $\alpha_{o}^{(i)}$  and  $\tau_{rec,discr}^{(i)}$ , which 294 characterise discretised individual within-host dynamics (as described above).
- 295 The number of antigen tests,  $Z^{(i)}(t)$ , conducted by individual i at the start of day 296  $t$  of the simulation (for each positive integer value of  $t$ ). We considered two 297 possibilities:
- 298 i. In Figure 2F, we sampled  $Z^{(i)}(t)$  from a Poisson distribution with mean  $1/T$ 299 (independently for each individual and each day, where a range of  $T$  values

300 were considered). This is consistent with our analytic outbreak risk derivation 301 (since an exponentially distributed duration between tests, with mean  $T$ 302 (measured in days), leads to a Poisson-distributed number of tests being taken 303 each day, with mean  $1/T$ , although note that tests may be taken at any time of 304 day in the analytic approach), but leads to the possibility of more than one daily 305 test.

 ii. In **Supplementary Figure 3B**, we instead considered a fixed (constant) gap of length  $T$  between days on which a test is taken. For each individual, we sampled the first day of the simulation on which a test is conducted uniformly between 1 and  $T$  (independently for each individual).

310

311 The outbreak simulation algorithm consists of the following steps:

- 312 1. Initialise the time at  $t = 0$  days and the status of each host at  $Y^{(i)} = S$ .
- 313 2. Sample a single initial infected host, i, according to the relative susceptibilities,  $\eta_i$ 314 (i.e., host *j* is selected with probability  $\eta_j / \sum_{k=1}^N \eta_k$ ). Set  $Y^{(i)} = U$  and the infection time,  $t_{\rm inf}^{(t)}$ 315 time,  $t_{\text{inf}}^{(i)} = 0$ .
- 316 3. While  $\sum_{i=1}^n \mathbf{1}_{\{U, O, D\}}(Y^{(i)}) > 0$  (i.e., while the number of active infections is greater 317 than zero), repeat the following steps:
- 318 a. Increase the simulation time, t, by 1 day (i.e., set  $t = (t + 1)$ ).
- 319 b. For each i such that both  $Y^{(i)} \in \{U, O, D\}$  and  $\left(t_{\text{inf}}^{(i)} + \tau_{\text{rec,diser}}^{(i)}\right) = t$ , set  $Y^{(i)} = R$ 320 (recovery/loss of infectiousness).
- 321 c. For each i such that  $Y^{(i)} = 0$ , set  $Y^{(i)} = D$  (day after symptom onset).
- 322 d. For each i such that  $Y^{(i)} = U$ , carry out the following steps (testing process):
- 323 i. Generate a random number,  $r$ , uniformly distributed between 0 and 1.

324 ii. If 
$$
r < 1 - \left(1 - p_{+, \text{disc}}^{(i)} \left( t - t_{\text{inf}}^{(i)} \right) \right)^{Z^{(i)}(t)}
$$
, set  $Y^{(i)} = D$ .

325 e. For each i such that both  $Y^{(i)} = U$  and  $\left(t_{\text{inf}}^{(i)} + \tau_{\text{inc,discr}}^{(i)}\right) = t$ , set  $Y^{(i)} = 0$ 326 (symptom onset).

327 f. Calculate the total infectious pressure exerted on each susceptible individual 328 over the current simulation day,

329 
$$
\lambda(t) = \frac{1}{N} \left( \sum_{j=1}^{N} \left( \mathbf{1}_{U}(Y^{(j)}) + \alpha_o^{(j)} \mathbf{1}_{O}(Y^{(j)}) + \alpha_d \mathbf{1}_{D}(Y^{(j)}) \right) \beta_{u, \text{discr}}^{(j)}(t - t_{inf}^{(j)}) \right).
$$

330 g. For each i such that  $Y^{(i)} = S$ , carry out the following steps (transmission 331 process):

332 i. Generate a random number,  $r$ , uniformly distributed between 0 and 1.

ii. If  $r < 1 - \exp(-\eta^{(i)} \lambda(t))$ , set  $Y^{(i)} = U$  and  $t_{inf}^{(i)}$ 333 ii. If  $r < 1 - \exp(-\eta^{(i)} \lambda(t))$ , set  $Y^{(i)} = U$  and  $t_{inf}^{(i)} = t$ .

334 For each testing scenario considered, we carried out 100,000 model 335 simulations in a population of  $N = 1,000$  individuals. The outbreak risk was estimated 336 as the proportion of model simulations in which the total number of individuals ever 337 infected exceeded 10% of the total population (see **Supplementary Figure 2**). 338

## 339 **Supplementary Table 1**



340 **Supplementary Table 1. Baseline parameter values used in our analyses.** These parameter values were used in our analyses except where explicitly stated 341 otherwise. Note that the values of the within-host model parameters  $b, \gamma, \delta$  and  $\tau_{inc}$  here are population median estimates (fixed effects); estimates of random<br>342 effects are given in **Supplementary Table 2** (the 342 effects are given in **Supplementary Table 2** (the random effects were used to account for heterogeneous within-host dynamics in **Figure 4**).

# 344 **Supplementary Table 2**



345 **Supplementary Table 2. Estimated random effects for within-host model parameters.** The estimated quantities correspond to the standard deviation of

346 the natural logarithm of the parameters  $b$ ,  $\gamma$ ,  $\delta$  and  $\tau_{inc}$  between different individuals (see the section "Within-host model and parameter estimation" of 347 **Methods** in the main text for details; population

347 **Methods** in the main text for details; population parameter values (fixed effects) and units are given in **Supplementary Table 1**).

### **Supplementary Figure 1**



 **Supplementary Figure 1. Reconstructed viral dynamics for individual hosts.** Individual-level model fits to longitudinal SARS-CoV-2 viral load data using a target cell-limited within-host model are shown (see the section "Within-host model and parameter estimation" of **Methods** in the main text). Overall, we used data from 521 individuals with omicron variant infections (6) to characterise SARS- CoV-2 viral dynamics; here, individual model fits are shown for 100 randomly chosen individuals. In each panel (corresponding to a single individual), the dots indicate the measured viral load data, and the solid curves the estimated viral load at different times relative to symptom onset.

### **Supplementary Figure 2**



 **Supplementary Figure 2. Alternative estimation of the outbreak risk using a discrete-time, individual-based, stochastic outbreak simulation model. A**. Example discretised infectiousness profile of a single infected host when regular antigen testing does not take place. **B**. The output of two realisations of the stochastic outbreak simulation model. **C**. Histogram of total outbreak sizes (i.e., the total proportion of the population ever infected during the outbreak) over 100,000 model simulations. The vertical black dashed line indicates the assumed threshold for a major outbreak of 10% of the population being infected. Here (without regular antigen testing), the estimated outbreak risk (i.e., the proportion of model simulations classified as major outbreaks) is 0.58. Details of the stochastic simulation model are given in **Supplementary Note 5**.



 **Supplementary Figure 3. Effect of details of implementation of antigen testing in our modelling approach on the outbreak risk under regular antigen testing. A.** The outbreak risk for different values of the (mean) interval between antigen tests, comparing our default analytic approach using an expected infectiousness profile that averages over the individual infectiousness profiles of hosts with different detection times (blue), and a more complex approach in which variations in detection times are accounted for directly by sampling the detection times of a large number of individuals and using Eq. (2) to calculate the outbreak risk (red dashed). **B.** The outbreak risk for different values of the (mean) interval between tests, comparing our default analytic approach assuming an exponentially distributed interval between tests (black dashed), and both the analytic (blue) and simulation-based approaches (red crosses) under the alternative assumption of a fixed (constant) interval between tests. Note that in the analytic approach with a fixed interval, we used sampled detection times since the expected infectiousness profile was not readily available in this case. 

#### **Supplementary Figure 4**



 **Supplementary Figure 4. Effect of delayed and/or time-limited antigen testing. A**. The outbreak risk for different delays from the time of the first infection to the introduction of regular antigen testing, assuming an infinite duration of testing, and either 1 (blue), 2 (red) or 3 days (orange) between tests (on average). **B**. The outbreak risk for different durations of antigen testing, assuming a delay of one incubation period (4.6 days) from the first infection to the start of testing (i.e., testing starts following the detection of a symptomatic case), and either 1 (blue), 2 (red) or 3 days (orange) between tests (on average). **C**. The outbreak risk for different values of the (mean) interval between tests with a fixed total of 5 (blue), 10 (red), 20 (orange) or 40 (purple) tests available to each individual (on average), assuming a delay of one incubation period from the first infection to the start of testing.

# **Supplementary References**

- 1. van den Driessche, P. Reproduction numbers of infectious disease models. *Infect Dis Model* **2,** 288–303 (2017).
- 2. Norris, J. R. *Markov Chains*. *Cambridge Series in Statistical and Probabilistic Mathematics* (Cambridge University Press, 1997).
- 3. Jeong, Y. D. *et al.* Designing isolation guidelines for COVID-19 patients with rapid antigen tests. *Nature Communications 2022 13:1* **13,** 4910 (2022).
- 4. Boucau, J. *et al.* Duration of shedding of culturable virus in SARS-CoV-2 omicron (BA.1) infection. *New England Journal of Medicine* **387,** 275–277 (2022).
- 5. Hart, W. S. *et al.* Generation time of the alpha and delta SARS-CoV-2 variants: an epidemiological analysis. *Lancet Infect Dis* **22,** 603–610 (2022).
- 6. Hay, J. A. *et al.* Quantifying the impact of immune history and variant on SARS-CoV-2 viral kinetics and infection rebound: a retrospective cohort study. *Elife* **11,** e81849 (2022).